

# Phase I trial; HMR code: 24-003

<b>Submission date</b> 05/08/2024	<b>Recruitment status</b> Recruiting	<input checked="" type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
<b>Registration date</b> 12/08/2024	<b>Overall study status</b> Deferred	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
<b>Last Edited</b> 06/01/2025	<b>Condition category</b> Other	<input type="checkbox"/> Individual participant data <input checked="" type="checkbox"/> Record updated in last year

## Plain English Summary

The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

## Contact information

### Type(s)

Principal Investigator

### Contact name

Dr Adeep Puri

### Contact details

Hammersmith Medicines Research Limited  
Cumberland Avenue  
Park Royal  
London  
United Kingdom  
NW10 7EW  
+44 20 8961 4130  
rec@hmrlondon.com

### Type(s)

Public, Scientific

### Contact name

Dr Jeff Kent

### Contact details

455 E. Eisenhower Parkway  
Suite 300 PMB 1048  
Ann Arbor  
United States of America

MI 48108  
+1 734 887 9192  
info@slingtx.com

## Additional identifiers

### EudraCT/CTIS number

Nil known

### IRAS number

1010220

### ClinicalTrials.gov number

Nil known

### Secondary identifying numbers

IRAS 1010220; HMR code: 24-003; Sponsor code: SLG-TED-101

## Study information

### Scientific Title

Phase I trial; HMR code: 24-003 [The full scientific title will be published within 30 months after the end of the trial]

### Study hypothesis

The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

### Ethics approval required

Ethics approval required

### Ethics approval(s)

Approved 30/07/2024, London – Surrey Borders Research Ethics Committee (Equinox House, City Link, Nottingham, NG2 4LA, United Kingdom; +44 207 104 8057; surreyboundaries.rec@hra.nhs.uk), ref: 24/LO/0492

### Study design

Pharmacokinetic and bioavailability study in up to 20 healthy volunteers

### Primary study design

Interventional

### Secondary study design

### Study setting(s)

Other

### Study type(s)

Other

## **Participant information sheet**

Not available in web format

### **Condition**

Healthy volunteers

### **Interventions**

The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

### **Intervention Type**

Drug

### **Pharmaceutical study type(s)**

The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

### **Phase**

Phase I

### **Drug/device/biological/vaccine name(s)**

The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

### **Primary outcome measure**

The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

### **Secondary outcome measures**

The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

### **Overall study start date**

05/06/2024

### **Overall study end date**

08/08/2025

## **Eligibility**

### **Participant inclusion criteria**

Healthy volunteer

### **Participant type(s)**

Healthy volunteer

**Age group**

Adult

**Sex**

Both

**Target number of participants**

Up to 20

**Participant exclusion criteria**

The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

**Recruitment start date**

14/08/2024

**Recruitment end date**

08/05/2025

## Locations

**Countries of recruitment**

England

United Kingdom

**Study participating centre**

**Hammersmith Medicines Research Limited**

Cumberland Avenue

London

United Kingdom

NW10 7EW

## Sponsor information

**Organisation**

Sling Therapeutics, Inc.

**Sponsor details**

455 E. Eisenhower Parkway

Suite 300 PMB 1048

Ann Arbor

United States of America  
MI 48108  
+1 734 887 9192  
info@slingtx.com

**Sponsor type**

Industry

**Funder(s)**

**Funder type**

Industry

**Funder Name**

Sling Therapeutics, Inc.

**Results and Publications**

**Publication and dissemination plan**

Full trial details will be published up to 30 months after the end of the trial. Publication of some trial details is deferred because of the high commercial sensitivity of this Phase I study and the negligible benefit to the public of Phase I information. Results may be posted on or after the date of publication of full trial details.

**Intention to publish date**

08/02/2028

**Individual participant data (IPD) sharing plan**

The datasets generated and/or analysed during the current study are not expected to be made available because of their high commercial sensitivity and the negligible benefit to the public of publication of results of non-therapeutic clinical trials.

**IPD sharing plan summary**

Not expected to be made available